Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review

Clicks: 224
ID: 274199
2016
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
This systematic review found little published evidence to support an optimal dosage regimen or TDM targets for amikacin therapy. The use of alternative approaches, such as consensus opinion and a review of current practice, will be required to develop guidelines to maximize therapeutic outcomes and …
Reference Key
a2016theamikacin Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jenkins A;Thomson AH;Brown NM;Semple Y;Sluman C;MacGowan A;Lovering AM;Wiffen PJ; ;;
Journal The Journal of antimicrobial chemotherapy
Year 2016
DOI
DOI not found
URL
https://www.ncbi.nlm.nih.gov/pubmed/27494904
Keywords
systematic review National Center for Biotechnology Information NCBI NLM MEDLINE review humans pubmed abstract nih national institutes of health national library of medicine treatment outcome adult anti-bacterial agents / therapeutic use anti-bacterial agents / administration & dosage* dose-response relationship drug drug-related side effects and adverse reactions amikacin / adverse effects* anti-bacterial agents / adverse effects* drug monitoring* amikacin / therapeutic use amikacin / administration & dosage* anti-bacterial agents / blood amikacin / blood investigators=[] affs=[]) pmid:27494904 doi:10.1093/jac/dkw250 abi jenkins alison h thomson collabauthor(name='(bsac working party on therapeutic drug monitoring)' interrupted time series analysis

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.